Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ritlecitinib in Non-segmental Vitiligo (Tranquillo LTE)
NCT06163326Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Jan 2024
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 3 trial of ritlecitinib tosilate in Vitiligo, sponsored by Pfizer. Started Jan 2024; status: active, not recruiting.
02
Drugs
ritlecitinib tosilate
03
Conditions
Vitiligo
Beyond the preview
Go deeper on NCT06163326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06163326.